Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

NCT03148327 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Durvalumab (MEDI 4736)
RADIATION: Radiotherapy

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]